FIG 1.

Lung CFU counts in BALB/c mice after treatment. (A) Mice treated for 1 month with BPaL with or without an mTOR inhibitor, CC214-2 (CC214) or rapamycin (Rapa), or an mTOR inhibitor alone and for 2 months with the RHZE regimen with or without an mTOR inhibitor. (B) Relapse assessment after 12 weeks of treatment with RHZE with or without an mTOR inhibitor. (C) Relapse assessment after 8 weeks of treatment with BPaL with or without an mTOR inhibitor. The fractions above each regimen indicate the proportion of mice that relapsed after that treatment. Bars indicate median CFU numbers.